Il 10 clone jes3 19f1

Manufactured by BD

IL-10 (clone JES3-19F1) is a lab equipment product that detects the cytokine interleukin-10 (IL-10). IL-10 is an immunosuppressive cytokine that plays a role in regulating the immune response.

Automatically generated - may contain errors

Lab products found in correlation

Cd46 clone 344519, by R&D Systems (2 mentions) Il 4 clone 8d4 8, by BD (2 mentions) Fitc labeled anti cd19 clone 4g7 2e3, by R&D Systems (2 mentions) Apc labeled anti cd138 clone 359103, by R&D Systems (2 mentions) Apc labelled anti cd25 clone m a251, by BD (2 mentions) Recombinant human il 2 and il 10, by Thermo Fisher Scientific (2 mentions) Cd66b g10f5, by BioLegend (1 mentions) Duoset elisa development kit, by R&D Systems (1 mentions)

Spelling variants of this product

IL-10 (156 citations) Anti-IL-10-APC (clone JES3-19F1, (2 citations)

4 protocols using il 10 clone jes3 19f1

Stimulating T and B Cell Responses

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell stimulating antibodies to CD3 (clone OKT-3), CD28 (clone AF-342-PB) and CD46 (clone 344519) were all purchased from R&D Systems. Neutralizing antibodies to IL-4 (clone 8D4-8) and IL-10 (clone JES3-19F1) were both from BD Pharmingen. Antibodies used in flow cytometric analysis were FITC-labeled anti-CD46 (clone MEM-258), BV421-labeled anti-CD122 (clone TU27), PE-labeled anti-CD132 (clone AG184) from BioLegend, and FITC-labeled anti-CD19 (clone 4G7-2E3) and APC-labeled anti-CD138 (clone 359103), both from R&D Systems, while the APC-labelled anti-CD25 (clone M-A251) was purchased from BD Pharmingen. Recombinant human IL-2 and IL-10 were purchased from Pepro-Tech and soluble CD46 was prepared as previously described.¹⁰ The MMP-9 inhibitor was purchased from Calbiochem (CAS 1177749-58-4) and used at the concentrations indicated in the respective experiments.

Ellinghaus U., Cortini A., Pinder C.L., Le Friec G., Kemper C, & Vyse T.J. (2017). Dysregulated CD46 shedding interferes with Th1‐contraction in systemic lupus erythematosus. European Journal of Immunology, 47(7), 1200-1210.

+ Open protocol

+ Expand

Immune Cell Activation and Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell stimulating antibodies to CD3 (clone OKT‐3), CD28 (clone AF‐342‐PB) and CD46 (clone 344519) were all purchased from R&D Systems. Neutralizing antibodies to IL‐4 (clone 8D4‐8) and IL‐10 (clone JES3‐19F1) were both from BD Pharmingen. Antibodies used in flow cytometric analysis were FITC‐labeled anti‐CD46 (clone MEM‐258), BV421‐labeled anti‐CD122 (clone TU27), PE‐labeled anti‐CD132 (clone AG184) from BioLegend, and FITC‐labeled anti‐CD19 (clone 4G7‐2E3) and APC‐labeled anti‐CD138 (clone 359103), both from R&D Systems, while the APC‐labelled anti‐CD25 (clone M‐A251) was purchased from BD Pharmingen. Recombinant human IL‐2 and IL‐10 were purchased from PeproTech and soluble CD46 was prepared as previously described.¹⁰ The MMP‐9 inhibitor was purchased from Calbiochem (CAS 1177749‐58‐4) and used at the concentrations indicated in the respective experiments.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fluorochrome-labeled monoclonal antibodies used for the phenotypic and intracellular staining assay included CD3 (clone UCHT1), CD4 (clone RPA-T4), CD8 (clone SK1), CCR7 (clone 3D12), CXCR4 (clone12G5), CCR5 (clone 2D7), CD8 (clone RPA-T8), IFNγ (clone B27), TNFα (clone MAb11), MIP-1ß (clone D21-1351) from Becton-Dickinson Pharmingen (San Diego, CA); CD45RA (2H4), CD4 (clone T4D11) from Beckman Coulter (Fullerton, CA); CD38 (clone HB7), CD107a (clone H4A3), and IL10 (clone JES3-19F1) from BD Biosciences (San Jose, CA); HLADR (clone TU36), aqua amine reactive dye from Invitrogen (Carlsbad, CA); CD66b (G10F5) Biolegend (San Diego, CA); and IL17 (clone eBio64CAP17), IL2 (clone MQ1-17H12), from eBioscience (San Diego, CA). Optimum antibody titers were determined empirically for each antibody based on preliminary titration experiments using serial dilutions, which included the manufacturers’ recommended amounts. Flow cytometry data were acquired on an LSRII (BD Immunocytometry Systems, San Jose, CA) equipped with 405, 488, and 643 nm lasers and utilizing FACSDIVA software (BDIS). Analysis of cytometry data was done with FlowJo software (TreeStar, Ashland, OR). Results were recorded as the percentage of CD4+ or CD8+ T-cells expressing a given surface marker or combination of markers.

Smith-McCune K., Chen J.C., Greenblatt R.M., Shanmugasundaram U., Shacklett B.L., Hilton J.F., Johnson B., Irwin J.C, & Giudice L.C. (2015). Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study. PLoS ONE, 10(7), e0129769.

+ Open protocol

+ Expand

Cytokine Detection in T Cell Supernatants

Check if the same lab product or an alternative is used in the 5 most similar protocols

Culture supernatants from amplified T cell libraries assay were assayed for the presence of cytokines by ELISA. ELISA measurement of cytokines was performed with purified coating and biotinylated detection antibodies, as follows: IFN-γ, clone 2G1 and human IFN-γ mAb biotin-labeled (Thermo Scientific, Walthman, MA); IL-10, clone JES3-19F1 and biotin anti-human and viral IL-10 (BD Biosciences). Production of IL-17 and GM-CSF were measured with a DuoSet ELISA Development kit (R&D Systems, Minneapolis, MN). The absorbance was measured and analyzed on a microplate read (Bio-Rad, Hercules, CA).

Cao Y., Goods B.A., Raddassi K., Nepom G.T., Kwok W.W., Love J.C, & Hafler D.A. (2015). Distinct Inflammatory Profiles of Myelin-Reactive T cells from Patients with Multiple Sclerosis. Science translational medicine, 7(287), 287ra74.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!